A
Aimed bio
Innovative brain therapeutics leveraging BBB crossing technologies and precision medicine for neurodegenerative diseases
About Aimed bio
AIMEDBIO is a pioneering company in the field of brain therapeutics, focusing on the development of treatments for neurodegenerative diseases. The company leverages its proprietary Blood-Brain Barrier (BBB) crossing technologies and precision medicine platform to identify and target brain-specific conditions. AIMEDBIO operates in the healthcare and biotechnology market, primarily serving patients suffering from brain diseases such as neuro-oncology and neurology disorders. The business model revolves around extensive research and development (R&D) pipelines, which are aimed at creating efficient and effective brain-specific immune modulators and therapeutics. Revenue is generated through the development and commercialization of these advanced treatments. The company's long-standing expertise in brain research, combined with big data analysis, positions it as a leader in the field of brain disease treatment. AIMEDBIO's commitment to innovation and scientific breakthroughs continues to drive its mission of providing optimal solutions for individual patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Seoul, South Korea
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 83.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Aug 2026
- Capital deployed
- $31M
- Preferred round
- SERIES B
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Dec 2025 | $59M | — | Undisclosed | — |
| LATE VCOther financing | Jun 2025 | $43M | $171M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Aimed bio is 4.6K monthly website visits, down 34.3% over the last three months. Aimed bio's team grew 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Samsung Bioepis
Samsung C&T’s Engineering & Construction
Samsung BioLogics
InterVest
DS Asset Management- SFSamsung Life Science Fund
- SFSamsung Life Public Welfare Foundation
Mint Venture Partners
Other known investors1 additional known investor
Samsung Medical Center
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aimed bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aimed bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.